NEW YORK, February 24, 2017 /PRNewswire/ --
This morning, Stock-Callers.com tracks the current performances of Alkermes
On Thursday, shares in Dublin, Ireland headquartered Alkermes PLC recorded a trading volume of 776,962 shares. The stock ended the session 1.35% lower at $52.57. The Company's shares are trading 5.40% above their 200-day moving average. Moreover, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have a Relative Strength Index (RSI) of 38.52.
On February 15th, 2017, Alkermes announced that total revenues for Q4 2016 were $213.5 million, up 31% compared to $163.1 million for Q4 2015. The Company's net loss on US (GAAP) basis was $21.1 million, or a basic and diluted GAAP loss per share of $0.14, compared to GAAP net loss of $69.4 million, or a basic and diluted GAAP loss per share of $0.46, for Q4 2015. ALKS complete research report is just a click away and free at:
Wayne, Pennsylvania headquartered Teleflex Inc.'s stock closed the day 0.05% lower at $183.92. A total volume of 557,481 shares was traded, which was above their three months average volume of 351,080 shares. The Company's shares have advanced 11.79% in the past month, 22.30% over the previous three months, and 14.13% on an YTD basis. The stock is trading 10.51% and 9.89% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Teleflex, which designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide, have an RSI of 81.95.
On February 23rd, 2017, Teleflex announced that Benson Smith will retire from his position as Chief Executive Officer, effective on December 31st, 2017. Mr. Smith, a Teleflex's Board member since 2005, will continue to serve as Teleflex's Chairman of the Board. He has been nominated by Teleflex's Board of Directors to serve for another three-year term if elected by Teleflex's stockholders at the 2017 annual meeting to be held in May, 2017. The complimentary report on TFX can be downloaded at:
Shares in Seattle, Washington headquartered Cascadian Therapeutics Inc. recorded a trading volume of 251,498 shares, and ended yesterday's trading session 7.40% lower at $3.88. The stock has advanced 4.30% in the past month. The Company's shares are trading below their 50-day moving average by 14.05%. Furthermore, shares of Cascadian Therapeutics, which engages in the research and development of therapeutic products for the treatment of cancer, have an RSI of 37.60.
As per a SEC filing dated February 03rd, 2017, Cascadian Therapeutics entered into a letter agreement with each of BVF Partners L.P., Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and BVF Partners OS Ltd. (collectively, "BVF") on January 11th, 2016. Under the Letter Agreement, among other things, the Company had agreed to nominate up to two individuals designated by BVF to the Company's Board of Directors and BVF agreed to certain standstill restrictions. On February 02nd, 2017, the Company received a notice from BVF terminating the Letter Agreement. Pursuant to the terms of the Letter Agreement, such termination will be effective March 04th, 2017, which is 30 days after receipt of the Notice. Upon the termination effectiveness, neither the Company nor BVF will have any continuing obligations under the Letter Agreement. Sign up for your complimentary research report on CASC at:
Boston, Massachusetts headquartered InspireMD Inc.'s stock finished Thursday's session 7.00% higher at $2.14 with a total trading volume of 63,312 shares. The Company's shares are trading above their 200-day moving average by 65.11%. Shares of the company, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 43.45.
On February 17th, 2017, InspireMD reported that revenue for Q4 2016 was $322,000, compared to $516,000 during Q4 2015. The Company's net loss for Q4 2016 totaled $2,268,000, or $0.88 per basic and diluted share, compared to a net loss of $2,854,000, or $9.34 per basic and diluted share, in Q4 2015. Get free access to your research report on NSPR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All